2017-03-23,Heat Biologics Prices Offering Of 5,000,000 Shares Of Common Stock
2017-03-22,Heat Biologics Announces Proposed Public Offering Of Common Stock
2017-03-21,Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results In Patients Treated With HS-110 In Combination With A Checkpoint Inhibitor
2017-03-16,Florida Department Of Health Awards Three-Year Grant To Develop Gp96-based Zika Vaccine
2017-03-13,Heat Biologics Meets Efficacy Endpoint In Its Phase 1b Lung Cancer Trial To Progress To Phase 2
2017-03-09,Heat Biologics To Present At 29th Annual ROTH Conference
2017-03-08,Heat Biologics Announces Agreement To Acquire Pelican Therapeutics
2017-03-02,Heat Biologics To Present At The American Association For Cancer Research (AACR) Annual Meeting
2017-02-17,Heat Biologics Presents Immune Data On Its HS-410 Phase 2 Bladder Cancer Trial At The Genitourinary Cancers Symposium
2017-02-14,Heat Biologics To Present At The Genitourinary Cancers Symposium
2017-01-27,These 5 Stocks Under $10 Could Get Hot Soon
2017-01-24,Heat Biologics To Present At NobleCon13
2017-01-05,Heat Biologics To Present At Biotech Showcase 2017 Conference In San Francisco
2017-01-04,Heat Biologics Appoints Jeff Hutchins, Ph.D., As Chief Scientific Officer
2016-12-06,Heat Biologics Presents Topline HS-110/Nivolumab Combination Lung Cancer Results
2016-12-01,Rosen Law Firm Closes Investigation And Concludes There Is No Basis For Securities Claims Against HTBX
2016-12-01,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Heat Biologics, Inc. (HTBX)
2016-12-01,INVESTOR LOSS ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Heat Biologics, Inc. - HTBX
2016-11-30,Heat Biologics Presents Topline HS-410 Phase 2 Bladder Cancer Results At The Society Of Urological Oncology Annual Meeting
2016-11-17,Heat Biologics To Present Topline HS-110/Nivolumab Combination Phase Ib Lung Cancer Results At The International Society For The Study Of Lung Cancer Annual Meeting
2016-11-16,Heat Biologics To Present Topline HS-410 Phase II Bladder Cancer Results At The Society Of Urological Oncology Annual Meeting
2016-11-14,Heat Biologics Presents ComPACT Preclinical Data At The Society For Immunotherapy Of Cancer Annual Meeting
2016-11-10,Heat Biologics Provides Corporate Update And Reports Third Quarter 2016 Financial Results
2016-11-07,Heat Biologics To Present At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting
2016-10-25,Heat Biologics And University Of Miami Announce Zika Vaccine Collaboration
2016-10-17,Heat Biologics To Present At Two Upcoming Investor Conferences And Panel Discussion
2016-10-13,Heat Biologics Remains On Track To Achieve Â Multiple Topline Data Readouts This Quarter
2016-10-11,Heat Biologics Selects Adaptive Biotechnologies To Discover Potential Clinical Biomarkers To Advance Novel Immunotherapies
2016-10-07,Heat Biologics Substantially Reduces Debt And Reports Proceeds Of Approximately $2.8 Million Year-to-Date From The Exercise Of Warrants
2016-09-13,Heat Biologics To Present At Two Upcoming Investor Conferences
2016-08-15,Heat Biologics Provides Corporate Update And Reports Second Quarter 2016 Financial Results
2016-07-22,Heat Biologics Announces Suspension Of Proposed Public Offering Of Common Stock
2016-07-21,Heat Biologics Announces Proposed Public Offering Of Common Stock
2016-06-06,Heat Biologics Presents A Poster On Its HS-110/Nivolumab Combination Phase 1b Non-Small Cell Lung Cancer Trial At ASCO Annual Meeting
2016-05-27,7 Stocks Under $10 to Trade for Big Profits
2016-05-11,Heat Biologics Reports First Quarter 2016 Financial Results
2016-04-26,Heat Biologics To Present At PIONEERS 2016, Presented By Joseph Gunnar & Co.
2016-04-25,8 Breakout Stocks Under $10 to Trade for Big Profits
2016-04-25,Heat Biologics Appoints Dr. John Prendergast To Board Of Directors
2016-04-18,Heat Biologics And OncoSec Present Data At The American Conference For Cancer Research (AACR) Annual Meeting
2016-04-18,OncoSec And Heat Biologics Present Data At The American Conference For Cancer Research (AACR) Annual Meeting
2016-04-12,Heat Biologics To Present At The American Association For Cancer Research (AACR) Annual Meeting
2016-04-07,Heat Biologics Announces Cost-Saving Measures And Focused Corporate Strategy To Achieve Important Clinical Milestones
2016-03-30,Heat Biologics To Participate In The 6th Annual Cancer Immunotherapy: A Long-Awaited Reality Conference
2016-03-23,Heat Biologics Announces Closing Of Public Offering
2016-03-18,Heat Biologics Announces Public Offering Of Common Stock And Warrants
2016-03-09,Heat Biologics' CSO To Participate In The 27th Annual Cancer Progress Conference By Defined Health
2016-03-07,Heat Biologics Presents Positive ComPACT Preclinical Data At The Keystone Symposia
2016-03-04,Heat Biologics To Present At The 28th Annual ROTH Conference
2016-02-25,Heat Biologics Provides Update On Its HS-410 Phase 2 Monotherapy Bladder Cancer Trial Arm
2016-02-18,Heat Biologics Reports Fiscal Year 2015 Financial Results
2016-02-10,FDA Lifts Heat Biologics Partial Clinical Hold
2016-02-03,Heat Biologics Reports Update On Its HS-410 Phase 2 Bladder Cancer Trial
2016-01-26,Heat Biologics CSO To Present Interim Results From The Monotherapy Arm In Its Ongoing HS-410 Phase 2 Bladder Cancer Trial At The Phacilitate Immunotherapy World Conference
2016-01-07,Heat Biologics To Present At Biotech Showcase 2016
2015-12-01,Heat Biologics Appoints Timothy Creech As Chief Financial Officer
2015-11-18,Heat Biologics Selected As One Of Informa's 2015 Top 10 Immuno-Oncology Companies To Watch
2015-11-06,Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting
2015-11-03,Results Of Heat Biologics' HS-410 Phase 1 Safety Trial In Non-Muscle Invasive Bladder Cancer To Be Presented At SITC Annual Meeting
2015-10-30,Heat Biologics Releases Third Quarter 2015 Financial Results
2015-10-14,Heat Biologics Expands Scientific And Clinical Advisory Board With Appointments Of Drs. Holbrook Kohrt And Kapil Dhingra
2015-10-08,Heat Biologics Completes Patient Enrollment For Randomized Arms Of Its Phase 2 HS-410 Bladder Cancer Trial
2015-10-07,Heat Biologics To Participate In The Annual Prostate Cancer Foundation Scientific Retreat
2015-09-16,Heat Biologics To Present New Data On Its ComPACT Platform At The CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference
2015-09-02,Heat Biologics, Inc. To Present At The 17th Annual Global Investment Conference
2015-09-01,Heat Biologics Announces Clinical Trial Combining HS-110 And PD-1 Checkpoint Inhibitor In NSCLC
2015-08-13,Heat Biologics Announces Financial Results For The Second Quarter Ended June 30, 2015
2015-07-28,4 Breakout Stocks Under $10 Making Big Moves
2015-07-27,Heat Biologics, Inc. Announces Promotions Of Taylor Schreiber, M.D., Ph.D., To Chief Scientific Officer, And Melissa Price, Ph.D., To Vice President Of Product Development
2015-07-01,Heat Biologics, Inc. To Present At The Cantor Fitzgerald Healthcare Conference
2015-06-15,Heat Biologics Announces Development Of ComPACT, A Next Generation Combination Immunotherapy Platform
2015-05-29,Heat Biologics, Inc. To Present Interim Immune Response Data From Ongoing Phase II Trial With HS-110 In Advanced NSCLC At ASCO
2015-05-21,Heat Biologics, Inc. To Present At The Marcum Microcap Conference
2015-05-14,Heat Biologics Announces Financial Results For The First Quarter Ended March 31, 2015
2015-05-11,CORRECTING And REPLACING -- Heat Biologics Announces Initiation Of Phase 1b Trial Of Viagenpumatucel-L (HS-110) In Non-Small Cell Lung Cancer (NSCLC)
2015-05-11,Heat Biologics Announces Initiation Of Phase 1b Trial Of Viagenpumatucel-L (HS-110) In Non-Small Cell Lung Cancer (NSCLC)
2015-04-22,Heat Biologics, Inc. To Present At The 2015 American Association For Cancer Research Annual Meeting
2015-04-15,Heat Biologics, Inc. To Present At The 2015 American Association For Cancer Research Annual Meeting
2015-03-27,Heat Biologics Announces Financial Results For The Year Ended December 31, 2014
2015-03-16,Heat Biologics, Inc. Announces Closing Of Public Offering Of Common Stock And Full Exercise Of The Underwriters' Over-Allotment Option
2015-03-10,Heat Biologics, Inc. Announces Pricing Of Public Offering Of $10,660,000 Of Common Stock
2015-03-10,Heat Biologics, Inc. Announces Proposed Public Offering Of Common Stock
2015-03-09,Heat Biologics, Inc. Receives US FDA Fast Track Designation For HS-410 (Vesigenurtacel L) In Combination With BCG For The Treatment Of Non-Muscle Invasive Bladder Cancer
2015-02-26,Heat Biologics Provides Update At Key Opinion Leader Event
2015-02-23,Heat Biologics, Inc. To Host Key Opinion Leader Meeting On February 26 In New York City
2015-02-18,Heat Biologics, Inc. And OncoSec Medical Inc. Announce Collaboration To Evaluate Combination Of Immunotherapy Platforms
2015-02-18,OncoSec Medical Inc. And Heat Biologics, Inc. Announce Collaboration To Evaluate Combination Of Immunotherapy Platforms
2015-02-11,Heat Biologics Presents Positive Preclinical Data On A Novel Approach To Combination Immunotherapy At The Keystone Symposia On Tumor Immunology
2015-02-02,Heat Biologics, Inc. To Present At The BIO CEO & Investor Conference
2015-02-02,Heat Biologics, Inc. Outlines 2015 Corporate Objectives
2015-01-26,Heat Biologics, Inc. Presents Positive Immunological Data On HS-410 In Non-Muscle Invasive Bladder Cancer At The 7th Annual Phacilitate Immunotherapy Forum 2015
2015-01-23,Heat Biologics, Inc. To Present At The 7th Annual Phacilitate Immunotherapy Forum 2015
2015-01-15,Heat Biologics, Inc. To Present At The Noble Financial Capital Markets Equity Conference
2014-12-02,Heat Biologics, Inc. Expands Product Development Team To Support Development Of Lead Product Candidates In Oncology
2014-12-01,Heat Biologics, Inc. To Present At The Piper Jaffray 26th Annual Healthcare Conference On December 2 In New York
2014-11-14,Heat Biologics, Inc. Reports 2014 Third Quarter Financial Results
2014-10-27,Heat Biologics, Inc. Commences Patient Dosing Of Phase 2 Clinical Study Of Vesigenurtacel-L For The Treatment Of Bladder Cancer
2014-10-02,Heat Biologics, Inc. Completes Enrollment Of Phase 1 Clinical Trial Of Vesigenurtacel-L For The Treatment Of Bladder Cancer Required To Advance To Phase 2
2014-09-30,Heat Biologics, Inc. To Present At The 13th Annual BIO Investor Forum In San Francisco On Tuesday, October 7, 2014
2014-09-18,Heat Biologics Commences Patient Dosing In Phase 2 Study Of Viagenpumatucel-L For The Treatment Of Non-Small Cell Lung Cancer
2014-09-04,Heat Biologics, Inc. To Present And Webcast At Two Investor Conferences In September
2014-08-25,Heat Biologics, Inc. Closes On Up To $7.5 Million Secured Term Loan Facility
2014-08-14,Heat Biologics, Inc. Reports 2014 Second Quarter Financial Results
2014-08-13,3 Stocks Advancing The Drugs Industry
2014-08-07,3 Stocks Boosting The Drugs Industry Higher
2014-08-04,Heat Biologics Amends Bladder Cancer Protocol For Early Advancement Into Phase 2 Clinical Studies
2014-07-29,3 Drugs Stocks Pushing The Industry Higher
2014-07-28,3 Stocks Pushing The Drugs Industry Lower
2014-05-29,3 Drugs Stocks Driving The Industry Higher
2014-03-21,3 Stocks Under $10 Making Big Moves
2013-08-24,A Time to Test Biotechs' Strength
,
,
2017-03-23,Heat Biologics Prices Offering Of 5,000,000 Shares Of Common Stock
2017-03-22,Heat Biologics Announces Proposed Public Offering Of Common Stock
2017-03-21,Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results In Patients Treated With HS-110 In Combination With A Checkpoint Inhibitor
2017-03-16,Florida Department Of Health Awards Three-Year Grant To Develop Gp96-based Zika Vaccine
2017-03-13,Heat Biologics Meets Efficacy Endpoint In Its Phase 1b Lung Cancer Trial To Progress To Phase 2
2017-03-09,Heat Biologics To Present At 29th Annual ROTH Conference
2017-03-08,Heat Biologics Announces Agreement To Acquire Pelican Therapeutics
2017-03-02,Heat Biologics To Present At The American Association For Cancer Research (AACR) Annual Meeting
2017-02-17,Heat Biologics Presents Immune Data On Its HS-410 Phase 2 Bladder Cancer Trial At The Genitourinary Cancers Symposium
2017-02-14,Heat Biologics To Present At The Genitourinary Cancers Symposium
2017-01-27,These 5 Stocks Under $10 Could Get Hot Soon
2017-01-24,Heat Biologics To Present At NobleCon13
2017-01-05,Heat Biologics To Present At Biotech Showcase 2017 Conference In San Francisco
2017-01-04,Heat Biologics Appoints Jeff Hutchins, Ph.D., As Chief Scientific Officer
2016-12-06,Heat Biologics Presents Topline HS-110/Nivolumab Combination Lung Cancer Results
2016-12-01,Rosen Law Firm Closes Investigation And Concludes There Is No Basis For Securities Claims Against HTBX
2016-12-01,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Heat Biologics, Inc. (HTBX)
2016-12-01,INVESTOR LOSS ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Heat Biologics, Inc. - HTBX
2016-11-30,Heat Biologics Presents Topline HS-410 Phase 2 Bladder Cancer Results At The Society Of Urological Oncology Annual Meeting
2016-11-17,Heat Biologics To Present Topline HS-110/Nivolumab Combination Phase Ib Lung Cancer Results At The International Society For The Study Of Lung Cancer Annual Meeting
2016-11-16,Heat Biologics To Present Topline HS-410 Phase II Bladder Cancer Results At The Society Of Urological Oncology Annual Meeting
2016-11-14,Heat Biologics Presents ComPACT Preclinical Data At The Society For Immunotherapy Of Cancer Annual Meeting
2016-11-10,Heat Biologics Provides Corporate Update And Reports Third Quarter 2016 Financial Results
2016-11-07,Heat Biologics To Present At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting
2016-10-25,Heat Biologics And University Of Miami Announce Zika Vaccine Collaboration
2016-10-17,Heat Biologics To Present At Two Upcoming Investor Conferences And Panel Discussion
2016-10-13,Heat Biologics Remains On Track To Achieve Â Multiple Topline Data Readouts This Quarter
2016-10-11,Heat Biologics Selects Adaptive Biotechnologies To Discover Potential Clinical Biomarkers To Advance Novel Immunotherapies
2016-10-07,Heat Biologics Substantially Reduces Debt And Reports Proceeds Of Approximately $2.8 Million Year-to-Date From The Exercise Of Warrants
2016-09-13,Heat Biologics To Present At Two Upcoming Investor Conferences
2016-08-15,Heat Biologics Provides Corporate Update And Reports Second Quarter 2016 Financial Results
2016-07-22,Heat Biologics Announces Suspension Of Proposed Public Offering Of Common Stock
2016-07-21,Heat Biologics Announces Proposed Public Offering Of Common Stock
2016-06-06,Heat Biologics Presents A Poster On Its HS-110/Nivolumab Combination Phase 1b Non-Small Cell Lung Cancer Trial At ASCO Annual Meeting
2016-05-27,7 Stocks Under $10 to Trade for Big Profits
2016-05-11,Heat Biologics Reports First Quarter 2016 Financial Results
2016-04-26,Heat Biologics To Present At PIONEERS 2016, Presented By Joseph Gunnar & Co.
2016-04-25,8 Breakout Stocks Under $10 to Trade for Big Profits
2016-04-25,Heat Biologics Appoints Dr. John Prendergast To Board Of Directors
2016-04-18,Heat Biologics And OncoSec Present Data At The American Conference For Cancer Research (AACR) Annual Meeting
2016-04-18,OncoSec And Heat Biologics Present Data At The American Conference For Cancer Research (AACR) Annual Meeting
2016-04-12,Heat Biologics To Present At The American Association For Cancer Research (AACR) Annual Meeting
2016-04-07,Heat Biologics Announces Cost-Saving Measures And Focused Corporate Strategy To Achieve Important Clinical Milestones
2016-03-30,Heat Biologics To Participate In The 6th Annual Cancer Immunotherapy: A Long-Awaited Reality Conference
2016-03-23,Heat Biologics Announces Closing Of Public Offering
2016-03-18,Heat Biologics Announces Public Offering Of Common Stock And Warrants
2016-03-09,Heat Biologics' CSO To Participate In The 27th Annual Cancer Progress Conference By Defined Health
2016-03-07,Heat Biologics Presents Positive ComPACT Preclinical Data At The Keystone Symposia
2016-03-04,Heat Biologics To Present At The 28th Annual ROTH Conference
2016-02-25,Heat Biologics Provides Update On Its HS-410 Phase 2 Monotherapy Bladder Cancer Trial Arm
2016-02-18,Heat Biologics Reports Fiscal Year 2015 Financial Results
2016-02-10,FDA Lifts Heat Biologics Partial Clinical Hold
2016-02-03,Heat Biologics Reports Update On Its HS-410 Phase 2 Bladder Cancer Trial
2016-01-26,Heat Biologics CSO To Present Interim Results From The Monotherapy Arm In Its Ongoing HS-410 Phase 2 Bladder Cancer Trial At The Phacilitate Immunotherapy World Conference
2016-01-07,Heat Biologics To Present At Biotech Showcase 2016
2015-12-01,Heat Biologics Appoints Timothy Creech As Chief Financial Officer
2015-11-18,Heat Biologics Selected As One Of Informa's 2015 Top 10 Immuno-Oncology Companies To Watch
2015-11-06,Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results At The Society For Immunotherapy Of Cancer (SITC) Annual Meeting
2015-11-03,Results Of Heat Biologics' HS-410 Phase 1 Safety Trial In Non-Muscle Invasive Bladder Cancer To Be Presented At SITC Annual Meeting
2015-10-30,Heat Biologics Releases Third Quarter 2015 Financial Results
2015-10-14,Heat Biologics Expands Scientific And Clinical Advisory Board With Appointments Of Drs. Holbrook Kohrt And Kapil Dhingra
2015-10-08,Heat Biologics Completes Patient Enrollment For Randomized Arms Of Its Phase 2 HS-410 Bladder Cancer Trial
2015-10-07,Heat Biologics To Participate In The Annual Prostate Cancer Foundation Scientific Retreat
2015-09-16,Heat Biologics To Present New Data On Its ComPACT Platform At The CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference
2015-09-02,Heat Biologics, Inc. To Present At The 17th Annual Global Investment Conference
2015-09-01,Heat Biologics Announces Clinical Trial Combining HS-110 And PD-1 Checkpoint Inhibitor In NSCLC
2015-08-13,Heat Biologics Announces Financial Results For The Second Quarter Ended June 30, 2015
2015-07-28,4 Breakout Stocks Under $10 Making Big Moves
2015-07-27,Heat Biologics, Inc. Announces Promotions Of Taylor Schreiber, M.D., Ph.D., To Chief Scientific Officer, And Melissa Price, Ph.D., To Vice President Of Product Development
2015-07-01,Heat Biologics, Inc. To Present At The Cantor Fitzgerald Healthcare Conference
2015-06-15,Heat Biologics Announces Development Of ComPACT, A Next Generation Combination Immunotherapy Platform
2015-05-29,Heat Biologics, Inc. To Present Interim Immune Response Data From Ongoing Phase II Trial With HS-110 In Advanced NSCLC At ASCO
2015-05-21,Heat Biologics, Inc. To Present At The Marcum Microcap Conference
2015-05-14,Heat Biologics Announces Financial Results For The First Quarter Ended March 31, 2015
2015-05-11,CORRECTING And REPLACING -- Heat Biologics Announces Initiation Of Phase 1b Trial Of Viagenpumatucel-L (HS-110) In Non-Small Cell Lung Cancer (NSCLC)
2015-05-11,Heat Biologics Announces Initiation Of Phase 1b Trial Of Viagenpumatucel-L (HS-110) In Non-Small Cell Lung Cancer (NSCLC)
2015-04-22,Heat Biologics, Inc. To Present At The 2015 American Association For Cancer Research Annual Meeting
2015-04-15,Heat Biologics, Inc. To Present At The 2015 American Association For Cancer Research Annual Meeting
2015-03-27,Heat Biologics Announces Financial Results For The Year Ended December 31, 2014
2015-03-16,Heat Biologics, Inc. Announces Closing Of Public Offering Of Common Stock And Full Exercise Of The Underwriters' Over-Allotment Option
2015-03-10,Heat Biologics, Inc. Announces Pricing Of Public Offering Of $10,660,000 Of Common Stock
2015-03-10,Heat Biologics, Inc. Announces Proposed Public Offering Of Common Stock
2015-03-09,Heat Biologics, Inc. Receives US FDA Fast Track Designation For HS-410 (Vesigenurtacel L) In Combination With BCG For The Treatment Of Non-Muscle Invasive Bladder Cancer
2015-02-26,Heat Biologics Provides Update At Key Opinion Leader Event
2015-02-23,Heat Biologics, Inc. To Host Key Opinion Leader Meeting On February 26 In New York City
2015-02-18,Heat Biologics, Inc. And OncoSec Medical Inc. Announce Collaboration To Evaluate Combination Of Immunotherapy Platforms
2015-02-18,OncoSec Medical Inc. And Heat Biologics, Inc. Announce Collaboration To Evaluate Combination Of Immunotherapy Platforms
2015-02-11,Heat Biologics Presents Positive Preclinical Data On A Novel Approach To Combination Immunotherapy At The Keystone Symposia On Tumor Immunology
2015-02-02,Heat Biologics, Inc. To Present At The BIO CEO & Investor Conference
2015-02-02,Heat Biologics, Inc. Outlines 2015 Corporate Objectives
2015-01-26,Heat Biologics, Inc. Presents Positive Immunological Data On HS-410 In Non-Muscle Invasive Bladder Cancer At The 7th Annual Phacilitate Immunotherapy Forum 2015
2015-01-23,Heat Biologics, Inc. To Present At The 7th Annual Phacilitate Immunotherapy Forum 2015
2015-01-15,Heat Biologics, Inc. To Present At The Noble Financial Capital Markets Equity Conference
2014-12-02,Heat Biologics, Inc. Expands Product Development Team To Support Development Of Lead Product Candidates In Oncology
2014-12-01,Heat Biologics, Inc. To Present At The Piper Jaffray 26th Annual Healthcare Conference On December 2 In New York
2014-11-14,Heat Biologics, Inc. Reports 2014 Third Quarter Financial Results
2014-10-27,Heat Biologics, Inc. Commences Patient Dosing Of Phase 2 Clinical Study Of Vesigenurtacel-L For The Treatment Of Bladder Cancer
2014-10-02,Heat Biologics, Inc. Completes Enrollment Of Phase 1 Clinical Trial Of Vesigenurtacel-L For The Treatment Of Bladder Cancer Required To Advance To Phase 2
2014-09-30,Heat Biologics, Inc. To Present At The 13th Annual BIO Investor Forum In San Francisco On Tuesday, October 7, 2014
2014-09-18,Heat Biologics Commences Patient Dosing In Phase 2 Study Of Viagenpumatucel-L For The Treatment Of Non-Small Cell Lung Cancer
2014-09-04,Heat Biologics, Inc. To Present And Webcast At Two Investor Conferences In September
2014-08-25,Heat Biologics, Inc. Closes On Up To $7.5 Million Secured Term Loan Facility
2014-08-14,Heat Biologics, Inc. Reports 2014 Second Quarter Financial Results
2014-08-13,3 Stocks Advancing The Drugs Industry
2014-08-07,3 Stocks Boosting The Drugs Industry Higher
2014-08-04,Heat Biologics Amends Bladder Cancer Protocol For Early Advancement Into Phase 2 Clinical Studies
2014-07-29,3 Drugs Stocks Pushing The Industry Higher
2014-07-28,3 Stocks Pushing The Drugs Industry Lower
2014-05-29,3 Drugs Stocks Driving The Industry Higher
2014-03-21,3 Stocks Under $10 Making Big Moves
2013-08-24,A Time to Test Biotechs' Strength
,
,
